NCT05126342: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi |
|
|
| Not yet recruiting | 2 | 100 | NA | Niraparib, Zejula, Dostarlimab, TSR-042 | AGO Research GmbH, GlaxoSmithKline | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer | 11/24 | 11/26 | | |